Fragile X syndrome and targeted treatment trials - PubMed (original) (raw)

Review

Fragile X syndrome and targeted treatment trials

Randi Hagerman et al. Results Probl Cell Differ. 2012.

Abstract

Work in recent years has revealed an abundance of possible new treatment targets for fragile X syndrome (FXS). The use of animal models, including the fragile X knockout mouse which manifests a phenotype very similar to FXS in humans, has resulted in great strides in this direction of research. The lack of Fragile X Mental Retardation Protein (FMRP) in FXS causes dysregulation and usually overexpression of a number of its target genes, which can cause imbalances of neurotransmission and deficits in synaptic plasticity. The use of metabotropic glutamate receptor (mGluR) blockers and gamma amino-butyric acid (GABA) agonists have been shown to be efficacious in reversing cellular and behavioral phenotypes, and restoring proper brain connectivity in the mouse and fly models. Proposed new pharmacological treatments and educational interventions are discussed in this chapter. In combination, these various targeted treatments show promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by loss of FMRP, with possible translational applications to other neurodevelopmental disorders including autism.

PubMed Disclaimer

Cited by

The pathophysiology of fragile X (and what it teaches us about synapses).
Bhakar AL, Dölen G, Bear MF. Bhakar AL, et al. Annu Rev Neurosci. 2012;35:417-43. doi: 10.1146/annurev-neuro-060909-153138. Epub 2012 Apr 5. Annu Rev Neurosci. 2012. PMID: 22483044 Free PMC article. Review.
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.
Curie A, Yang K, Kirsch I, Gollub RL, des Portes V, Kaptchuk TJ, Jensen KB. Curie A, et al. PLoS One. 2015 Jul 30;10(7):e0133316. doi: 10.1371/journal.pone.0133316. eCollection 2015. PLoS One. 2015. PMID: 26226597 Free PMC article.
The clinical relevance of neuroplasticity in corticostriatal networks during operant learning.
Andrzejewski ME, McKee BL, Baldwin AE, Burns L, Hernandez P. Andrzejewski ME, et al. Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):2071-80. doi: 10.1016/j.neubiorev.2013.03.019. Epub 2013 Apr 5. Neurosci Biobehav Rev. 2013. PMID: 23567518 Free PMC article. Review.
FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States.
Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, Hagerman RJ. Tassone F, et al. Genome Med. 2012 Dec 21;4(12):100. doi: 10.1186/gm401. eCollection 2012. Genome Med. 2012. PMID: 23259642 Free PMC article.
Parental Perspectives on Pharmacological Clinical Trials: a Qualitative Study in Down Syndrome and Fragile X Syndrome.
Reines V, Charen K, Rosser T, Eisen A, Sherman SL, Visootsak J. Reines V, et al. J Genet Couns. 2017 Dec;26(6):1333-1340. doi: 10.1007/s10897-017-0111-x. Epub 2017 May 24. J Genet Couns. 2017. PMID: 28536925

References

1. Allen K, Gleeson J, et al. PAK3 mutation in nonsyndromic X-linked mental retardation. Nat Genet. 1998;20:25–30. - PubMed
1. Alloway TP, Alloway RG. Investigating the predictive roles of working memory and IQ in academic attainment. J Exp Child Psychol. 2010;106(1):20–29. - PubMed
1. Amaria RN, Billeisen LL, et al. Medication use in fragile X syndrome. Mental Health Asp Dev Dis. 2001;4(4):143–147.
1. Antar L, Afroz R, et al. Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci. 2004;24:2648–2655. - PMC - PubMed
1. Antar L, Li C, et al. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol Cell Neurosci. 2006;32:37–48. - PubMed

Fragile X syndrome and targeted treatment trials - PubMed (original) (raw)